Section Arrow
Quote
AUPH.NASDAQ
- Aurinia Pharmaceuticals
Quotes are at least 15-min delayed:2025/04/13 19:05 EDT
Last
 7.41
+0.07 (+0.95%)
Day High 
7.53 
Prev. Close
7.34 
1-M High
8.73 
Volume 
1.39M 
Bid
7.02
Ask
7.5
Day Low
7.29 
Open
7.34 
1-M Low
6.825 
Market Cap 
1.01B 
Currency USD 
P/E 182.5 
%Yield -- 
10-SMA 7.82 
20-SMA 8.11 
50-SMA 8.05 
52-W High 10.67 
52-W Low 4.71 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
0.04/0.96
Enterprise Value
1.07B
Balance Sheet
Book Value Per Share
2.75
Cash Flow
Cash Flow Yield
0.04
Income Statement
Total Revenue
235.13M
Operating Revenue Per Share
1.16
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
RXRXRecursion Pharmaceuticals5.76+1.25+27.72%-- 
THTXTheratechnologies1.94+0.61+45.86%-- 
CDTConduit Pharmaceuticals Inc0.9101-0.1599-14.94%-- 
PRTGPortage Biotech Inc8.59+3.49+68.43%0.17PE
HEPAHepion Pharmaceuticals0.422-0.0091-2.11%-- 
Quotes are at least 15-min delayed：2025/04/13 19:05 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmunediseases.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.